| Aug 28 |
Soleno wins FDA priority review for Prader-Willi therapy
|
| Aug 28 |
Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
|
| Aug 27 |
Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients
|
| Aug 27 |
Hain Celestial Posts Upbeat Q4 Earnings, Joins Soleno Therapeutics, Energizer Holdings And Other Big Stocks Moving Higher On Tuesday
|
| Aug 27 |
Soleno lead asset granted FDA priority review
|
| Aug 27 |
Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
|
| Aug 15 |
Soleno Therapeutics Announces Updates to its Board of Directors
|
| Aug 7 |
Soleno Therapeutics GAAP EPS of -$0.57 beats by $0.03
|
| Aug 7 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
| Jul 29 |
When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)?
|
